Singapore, 1 April 2025 – CDW Holding Limited, a SGX Mainboard-listed precision components specialist, announced today that its subsidiary ABio, in collaboration with Neoregen Biotech, is set to commence in vivo (animal-based) research for its next-generation Lipid Nanoparticle (LNP) technology in April 2025. This follows promising in vitro (cell-based) results, marking a pivotal step toward safer and more effective drug delivery systems for mRNA vaccines, cancer therapies, and gene treatments.
Key Milestones and Findings
- Successful In Vitro Phase: Tests demonstrated comparable cell penetration efficiency between traditional LNPs and CDW’s proprietary LNP-LANFA technology, with no significant cytotoxicity.
- Targeted Applications: LNPs were optimized for both precision cancer drug delivery and broad vaccine distribution.
- Next Steps: The in vivo phase, involving laboratory mice, will assess immune responses and protein production capabilities over 12 months. Pending success, the technology could be licensed to pharmaceutical partners.
Prof. Tadakatsu Mandai, Head of CDW’s Research Centre and a peer of Nobel laureate Prof. Akira Suzuki, spearheads the LANFA technology integration.
Mr. Kato Tomonori, CDW’s Chairman and CEO, stated: “This collaboration addresses critical limitations of current LNPs, such as temperature stability and allergic risks. A licensed product could revolutionize global drug delivery while generating significant revenue for CDW.”
The joint research aligns with CDW’s diversification into life sciences, aiming to commercialize innovations that enhance human health. Neoregen brings expertise in macromolecule delivery, bolstering the project’s potential across medicine, cosmetics, and healthcare. Further developments will be disclosed via SGXNet.
————
CDW Holding Limited (the “Company” and together with its subsidiaries, the “Group”) is a Japanese-managed precision components specialist serving the global market focusing on the production and supply of niche precision components for digital instrument panels in the automobile industry, notebook computers, consumer and information technology equipment, office equipment and electrical appliances, and an original equipment manufacturer. The Group is headquartered in Hong Kong and has operations in Japan, China, South Korea, Thailand and the Philippines. The Company has been identifying new businesses to invest in with the potential for growth and entered as part of its diversification strategy and has made forays into the Life Sciences sector since 2016. The Company’s aim for its Life Sciences business is to identify research-driven yet commercialisable projects that can have a positive impact on the quality of human life.
